For decades, depression was explained to patients using a simple framework: the brain had too little serotonin, and antidepressants would correct the imbalance. That explanation was always a simplification of far more complex neuroscience, and the clinical evidence has continued to complicate it. What it leaves completely unaddressed is why a meaningful portion of patients who take SSRIs as directed, at therapeutic doses, for adequate duration, experience no significant benefit at all.
The Serotonin Model and Its Limitations
Selective serotonin reuptake inhibitors (SSRIs, medications that increase serotonin availability between neurons by slowing its reabsorption) became the dominant first-line treatment for depression starting in the late 1980s. Research consistently documents their efficacy as a first-line treatment for many patients with depression and anxiety (National Institutes of Health). For a meaningful portion of those patients, adjusting serotonin availability is enough to produce significant symptom relief.
The limitation is not that SSRIs are ineffective. The limitation is that serotonin reuptake inhibition is a specific intervention targeting one set of neurological processes, and depression is not a single-mechanism condition. For patients whose depression does not primarily involve serotonin dysregulation, adjusting the serotonin system produces little to no benefit, not because their depression is untreatable but because the biological system driving it lies elsewhere.
Serotonin-norepinephrine reuptake inhibitors (SNRIs), which add norepinephrine to the target, expand the approach slightly but remain within the monoamine family of interventions. Cycling through multiple antidepressants within the same class of mechanism does not change the underlying logic. A patient who has not responded to two SSRIs and an SNRI has not had three different treatments. In a meaningful neurological sense, they have had variations of the same one. For a deeper look at how ketamine compares to antidepressants for depression, our earlier overview covers that ground in detail.
What the Glutamate System Does
Glutamate is the brain’s primary excitatory neurotransmitter, the chemical signal responsible for activating neurons and driving communication across synaptic connections throughout the brain and central nervous system (National Institutes of Health). While serotonin and norepinephrine play important roles in mood and arousal, glutamate operates at a more fundamental level, regulating how efficiently the brain forms, maintains, and reorganizes neural pathways.
This distinction matters for depression because emerging evidence points to glutamate system dysregulation as a factor in the subset of patients who do not respond to serotonin-targeted treatments. Specifically, the NMDA receptors (N-methyl-D-aspartate receptors, a class of glutamate receptor that controls how readily neurons respond to incoming signals and how readily new synaptic connections form) appear to play a role in the kind of neural pathway disruption that some forms of depression produce over time. When NMDA receptor activity becomes dysregulated, it can impair the brain’s capacity to form new connections in regions associated with mood regulation, motivation, and cognitive flexibility.
This is a different neurological problem than low serotonin availability, and it requires a different neurological intervention to address it.
How IV Ketamine Targets the Glutamate System
Ketamine is a non-competitive NMDA receptor antagonist, meaning it temporarily blocks NMDA receptor activity, which triggers a downstream cascade of neurological responses. When delivered intravenously at psychiatric dosing levels, IV ketamine‘s interaction with the glutamate system promotes neuroplasticity (the brain’s capacity to form and reorganize synaptic connections) and stimulates the release of proteins that support neuron growth and repair in areas where depression tends to cause structural change over time (National Institutes of Health).
The clinical result of this mechanism is antidepressant effects that arrive within hours rather than weeks. That speed reflects the different timescale on which glutamate-pathway interventions operate relative to serotonin-targeted ones. Where SSRIs require weeks of gradual neurotransmitter adjustment, ketamine’s effect on the glutamate system can produce measurable mood changes within a single session.
This is why IV ketamine is particularly meaningful for patients who have been through multiple rounds of serotonin-based treatment without finding relief. It is not a stronger version of what they have already tried. It is a different intervention targeting a different biological system.
What This Means for Patients Who Have Not Responded to Antidepressants
If you have completed two or more antidepressant trials at full therapeutic doses without sufficient improvement, the clinical term for your experience is treatment-resistant depression (TRD), and it is more common than most people realize. The research does not suggest that these patients have more severe depression or worse odds of recovery. It suggests that the dominant treatment model was not built around the pathway that drives their condition.
At Ketamine Wellness Infusions PA, we serve patients throughout Lower Merion Township and the greater Philadelphia area who have been in exactly this position. A full history of what you have tried, for how long, and what it produced is the starting point of every clinical conversation we have, because understanding the pattern of non-response is what tells us whether IV ketamine is likely to be the right fit. We encourage you to discuss your treatment history with your current provider and bring those details to your consultation with us.
For patients whose depression also carries a significant psychological or trauma-related dimension, we offer ketamine-assisted psychotherapy (KAP), which pairs the infusion with structured therapeutic support before, during, and after each session. Whether that integrated approach is the better fit for your situation is something we assess individually.
What to Expect Financially
Most insurance plans do not cover IV ketamine for depression, as it is administered off-label. We address this directly at the consultation rather than leaving it as a surprise. Our team provides billing codes that you may submit to your carrier for potential out-of-network reimbursement, and we recommend calling your carrier before beginning treatment to understand what your specific plan may cover. We accept cash and credit card and collect payment at the time of treatment.
For patients who need financing assistance, we are happy to help guide you through available options. Veterans receive a 20 percent discount on treatment, and healthcare workers receive a 10 percent discount. We do not believe the cost question should be avoided, and we make a point of answering it plainly before you commit to anything.
Frequently Asked Questions
Is the serotonin theory of depression completely wrong? Not entirely. Serotonin plays a meaningful role in mood regulation, and SSRIs provide real benefit for many patients. What the evidence complicates is the idea that low serotonin is the primary cause of depression in all cases, and that serotonin-targeted treatment is the appropriate approach for every patient. For patients who do not respond to SSRIs, the evidence increasingly points to the glutamate pathway as a more clinically relevant target.
If SSRIs didn’t work for me, does that mean IV ketamine will? Not automatically. IV ketamine has demonstrated meaningful antidepressant results for a significant portion of patients with treatment-resistant depression, but results vary by individual and we do not promise specific outcomes. A consultation that reviews your full medical and psychiatric history will help clarify whether you are a strong candidate and what a realistic response might look like. We encourage you to explore your options and discuss them with your provider.
Is targeting the glutamate system an experimental approach? No. Ketamine has been used in clinical settings for decades, and research on its antidepressant mechanism through the glutamate system spans more than 20 years of peer-reviewed study. The application of this mechanism for treatment-resistant depression is supported by substantial published evidence and recognized by major mental health research institutions including the National Institute of Mental Health.
How does the infusion itself feel? Many patients experience mild dissociation, a temporary alteration in how they perceive their surroundings and sense of time, during the infusion. This is an expected effect of ketamine at psychiatric dosing levels and resolves quickly once the session ends. Our founder, Jill Gabay, CRNA, is present and monitoring throughout every session. Most patients find the experience manageable once they understand what to expect, and many describe later sessions as deeply settling.
Can I come for a consultation if I am currently on antidepressants? Yes. Your full current medication list is reviewed at the consultation. Some medications may need to be temporarily adjusted before or during treatment to support the best possible response to ketamine, but in many cases existing antidepressants can be continued. Any changes to your current regimen should be made in coordination with your prescribing provider.
Key Takeaways
- The serotonin model explains why SSRIs help many patients with depression but does not account for patients whose depression involves the glutamate system rather than the serotonin pathway.
- Glutamate is the brain’s primary excitatory neurotransmitter, and NMDA receptors within the glutamate system play a significant role in the kind of neural pathway disruption that drives treatment-resistant depression.
- IV ketamine targets NMDA receptors in the glutamate system directly, promoting neuroplasticity and producing antidepressant effects within hours rather than weeks.
- For patients who have not responded to two or more antidepressant trials, IV ketamine is not a stronger version of what they have already tried. It reaches a different biological system entirely.
- Results vary by individual. A consultation at Ketamine Wellness Infusions PA will determine whether IV ketamine is an appropriate fit for your history and diagnosis.
Not finding relief through antidepressants does not mean relief is out of reach. It may mean the treatment you have been given has been working on the wrong part of the brain. IV ketamine reaches a different system entirely, and for patients who recognize their experience in what this blog describes, that distinction is worth exploring further. Our team at Ketamine Wellness Infusions PA, serving Lower Merion Township and the greater Philadelphia area from our Bala Cynwyd clinic, is here to help you understand whether that next step makes sense for your situation. Call us at (484) 434-8963 or schedule a consultation to get started.
References
- National Institutes of Health. NMDA Receptor and Glutamate System in Ketamine’s Antidepressant Action. https://pmc.ncbi.nlm.nih.gov/articles/PMC5148235/
- National Institutes of Health. Glutamate Neurotransmitter System Overview. https://www.ncbi.nlm.nih.gov/books/NBK62187/
- National Institutes of Health. SSRIs as First-Line Treatment for Depression and Anxiety. https://pmc.ncbi.nlm.nih.gov/articles/PMC8395812/
Medical Disclaimer
The information in this blog is for educational purposes only and does not constitute medical advice. IV ketamine therapy for depression should only be pursued under the supervision of a licensed medical provider familiar with your full medical and psychiatric history. Individual results vary. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.